Abstract |
Therapeutic ultrasound approaches including high-intensity focused ultrasound (HIFU) are emerging as popular minimally invasive alternative treatments for localized, low-to-intermediate risk prostate cancer. FDA approval was recently granted for two ultrasound-guided HIFU devices. Clinical trials for devices using MRI guidance are ongoing. The current level of evidence for whole-gland ultrasound ablation suggests that its clinical efficacy and adverse event rates including erectile dysfunction and urinary incontinence are similar to current definitive therapies such as radical prostatectomy and external-beam radiotherapy. Short-term data suggest that more focal therapy could reduce the rates of adverse events.
|
Authors | Karthik M Sundaram, Sam S Chang, David F Penson, Sandeep Arora |
Journal | Seminars in interventional radiology
(Semin Intervent Radiol)
Vol. 34
Issue 2
Pg. 187-200
(Jun 2017)
ISSN: 0739-9529 [Print] United States |
PMID | 28579687
(Publication Type: Journal Article, Review)
|